Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same

• US 9,447,172 B2
• Filed: 12/27/2013
• Issued: 09/20/2016
• Est. Priority Date: 10/10/2007
• Status: Active Grant

• Current Assignee: Kyowa Kirin Co., Ltd. (Kirin Holdings Company Limited), La Jolla Institute For Allergy And Immunology
• Original Assignee: Kyowa Hakko Kirin Company Limited (Kirin Holdings Company Limited), La Jolla Institute For Allergy And Immunology
• Inventors: Kato, Shinichiro, Granger, Steve, Crotty, Shane, Rickert, Sandra, Koriazova, Lilia, Tahara, Tomoyuki
• Primary Examiner(s): Kolker, Daniel E
• Assistant Examiner(s): SNYDER, STUART
• Application Number:
  US14/142,520
• Publication Number:
  US 20140186370A1
• Time in Patent Office: 998 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07K 16/081 from DNA viruses
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]

Abstract

The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.

Claims

1. An isolated or purified antibody or subsequence thereof that binds to an H3L envelope protein of vaccinia virus, wherein the antibody or subsequence comprises heavy chain and light chain variable region sequence CDRs identical to heavy chain and light chain variable region sequence CDRs of an antibody produced by a hybridoma deposited at American Type Culture Collection having a deposit designation of PTA-10767.

3. The antibody or subsequence thereof of claim 1, wherein the antibody is produced by the hybridoma having the deposit designation of PTA-10767.

4. The antibody or subsequence of claim 1, wherein said antibody or subsequence thereof inhibits or competes for binding of the antibody produced by the hybridoma having the deposit designation of PTA-10767 to the H3L envelope protein of vaccinia virus.

5. The antibody of claim 1, wherein the antibody inhibits at least 50% of the binding of the antibody produced by the hybridoma having the deposit designation of PTA-10767 to the H3L envelope protein of vaccinia virus, as determined in an ELISA assay.

6. The antibody or subsequence of claim 1, wherein the antibody or subsequence thereof is humanized.

7. The antibody or subsequence thereof of claim 1, wherein the H3L envelope protein comprises or consists of a sequence set forth in SEQ ID NO:

53.

8. The antibody or subsequence thereof of claim 1, wherein the antibody or subsequence thereof binds to an epitope comprised within SEQ ID NO:

53.

9. The antibody or subsequence thereof of claim 1, wherein the isotype comprises IgM, IgG, IgA, IgD or IgE.

10. The antibody or subsequence thereof of claim 9, wherein the IgG or IgA isotype is selected from IgG1, IgG2, IgG3, and IgG4;

and IgA1 and IgA2.

11. The antibody subsequence of claim 1, wherein the subsequence is selected from Fab, Fab′

, F(ab′

)2, Fd, single-chain Fvs (scFv), and disulfide-linked Fvs (sdFv).

12. The antibody or subsequence thereof of claim 1, wherein the antibody or subsequence inhibits vaccinia virus infection of a cell, vaccinia virus proliferation or vaccinia virus replication in vitro or in vivo.

13. The antibody or subsequence thereof of claim 1, wherein the antibody or subsequence neutralizes IMV, CEV or EEV virus, as determined by a virus neutralization assay;

a complement-dependent virus neutralization assay, or a comet-tail inhibition assay.

14. The antibody or subsequence thereof of claim 1, wherein the antibody or subsequence binds to a vaccinia virus infected cell.

15. The antibody or subsequence thereof of claim 1, wherein the antibody or subsequence comprises a multimer.

16. The antibody or subsequence thereof of claim 1, further comprising one or more heterologous domains.

17. A pharmaceutical composition, comprising the antibody or subsequence thereof of claim 1, and a pharmaceutically acceptable excipient or carrier.

18. A composition, comprising at least two antibodies or subsequences thereof of claim 1.

19. A composition, comprising the antibody of claim 1 and an additional antibody that binds to a poxvirus protein.

2. An isolated or purified antibody or subsequence thereof that binds to an H3L envelope protein of vaccinia virus, wherein the antibody or subsequence comprises a heavy chain variable region sequence and a light chain variable region sequence identical to a heavy chain variable region sequence and a light chain variable region sequence of an antibody produced by a hybridoma deposited at American Type Culture Collection having a deposit designation of PTA-10767.